Table 3.

Anti-JCV Ab prevalence and antibody index by patients’ age and disease duration (years).

	Age Categories						Disease Duration Categories
n (%)	18–29	30–39	40–49	50–59	≥60	KW-H Post hoc	0–5	6–10	11–15	≥16
JCV+, n (%)	130 (52.4)	254 (64.1)	261 (68.5)	189 (70.8)	90 (79.6)	KW-H p < 0.0001; 18–29–40–49 p = 0.006; 18–29–50–59 p = 0.003; 18–29–≥60 p = 0.0003; Other p > 0.05	413 (62.3)	206 (66.2)	135 (69.6)	170 (71.7)	KW-H p = 0.03; 0–5–11–15 p = 0.06; 0–5–≥16 p = 0.009 Other p > 0.05
JCV−, n (%)	118 (47.6)	142 (35.9)	120 (31.5)	78 (29.2)	23 (20.4)		250 (37.7)	105 (33.8)	59 (30.4)	67 (28.3)
AI Mean	1.15	1.40	1.56	1.58	1.55	KW-H p = 0.0001; 18–29–30–39 p = 0.06; 18–29–40–49 p = 0.0002 18–29–50–59 p = 0.001; 18–29–≥60 p = 0.003; Other p > 0.05	1.38	1.45	1.44	1.61	KW-H p > 0.05
AI Median	0.44	0.75	1.28	1.37	0.96		0.74	1.11	0.89	1.40
AI Min	0.03	0.08	0.09	0.07	0.09		0.06	0.03	0.09	0.09
AI Max	4.09	4.51	4.50	4.07	4.15		4.27	4.51	4.50	4.21
AI SD	1.24	1.29	1.29	1.30	1.27		1.30	1.28	1.27	1.30

AI—antibodies index and SD—standard deviation.